Levetiracetam Tablet, Extended Release
Product Images NDC 68180-117

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 68180-117). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0a7e0c6f 1254 4654 A3c9 4813093479d6 01

Chemical structure diagram of the active ingredient Levetiracetam, showing its molecular composition including a pyrrolidone ring and associated functional groups.*

FDA Label Image

0a7e0c6f 1254 4654 A3c9 4813093479d6 02

A bar chart showing the percentage of patients by treatment group: placebo (7.4%), Immediate-release levetiracetam 1000 mg/day (37.1%), and Immediate-release levetiracetam 3000 mg/day (39.6%). Percentages are displayed above each bar with patient counts (N) noted. Bars for levetiracetam groups are marked with an asterisk indicating statistical significance versus placebo.*

FDA Label Image

0a7e0c6f 1254 4654 A3c9 4813093479d6 03

A vertical bar chart showing the percentage of patients across three groups: Placebo (6.3%), Immediate-release levetiracetam 1000 mg/day (20.8%), and Immediate-release levetiracetam 2000 mg/day (35.2%). The y-axis represents the percentage of patients from 0% to 45%. Asterisks indicate statistical significance versus placebo for both levetiracetam groups.*

FDA Label Image

0a7e0c6f 1254 4654 A3c9 4813093479d6 04

A bar chart comparing the percentage of patients for placebo and immediate-release levetiracetam 3000 mg/day. The placebo group (N=104) shows 14.4% of patients, while the immediate-release levetiracetam group (N=180) shows 39.4%, with a note indicating statistical significance versus placebo.*

FDA Label Image

0a7e0c6f 1254 4654 A3c9 4813093479d6 05

A bar chart comparing the percentage of patients between placebo and immediate-release levetiracetam groups. The chart shows 19.6% for placebo (N=97) and 44.6% for immediate-release levetiracetam (N=101), with a note indicating statistical significance versus placebo.*

FDA Label Image

0a7e0c6f 1254 4654 A3c9 4813093479d6 06

Levetiracetam Extended-Release Tablets USP 500 mg oral tablets label from Lupin Pharmaceuticals, Inc. The label includes NDC 68180-117-07, specifies 60 tablets per container, and advises once daily dosing. Storage instructions and manufacturer information for Lupin Limited, India are also shown, along with a barcode and a QR code linking to the medication guide.*

FDA Label Image

0a7e0c6f 1254 4654 A3c9 4813093479d6 07

Label for Levetiracetam Extended-Release Tablets USP 750 mg oral tablet, extended release, manufactured by Lupin Pharmaceuticals, Inc. The package contains 60 tablets and indicates once daily dosing. The label includes the NDC 68180-118-07, storage instructions, a barcode, and a QR code linking to the medication guide.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.